Organization (Industry)
ORGANON & CO.
ClinicalTrials.gov lists ORGANON & CO. as lead sponsor of 512 trials, counting the companies grouped under it. ORGANON & CO. itself has 425 active development programs and 149 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo https://www.organon.com/, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers ORGANON & CO. and 4 companies grouped under it: 512 lead-sponsored trials (505 its own, 7 in the grouped companies) and 4 legal-entity registrations (2 its own, 2 in the grouped companies).
Companies grouped under this page (4)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Dermavant Sciences GmbH | 4 | 0 |
| Alydia Health | 3 | 0 |
| ORGANON HEIST | 0 | 1 |
| ORGANON LLC | 0 | 1 |
Disease areas (86)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Dyslipidemias | 96 |
| Hyperlipidemias | 93 |
| Hypercholesterolemia | 87 |
| Rhinitis, Allergic | 69 |
| Asthma | 66 |
Showing 5 of 86 disease areas.
Trials by start year as sponsor or collaborator (32)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 3 |
| 2022 | 4 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 5 |
| 2017 | 1 |
| 2016 | 5 |
| 2015 | 5 |
Showing 10 of 32 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (425)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Asenapine | Schizophrenia | Phase 3 | 15 |
| Olanzapine | Schizophrenia | Phase 3 | 10 |
| Corifollitropin Alfa | Infertility | Phase 3 | 10 |
| Asenapine | Bipolar Disorder | Phase 3 | 9 |
| MK0653, ezetimibe | Hyperlipidemias | Phase 3 | 7 |
Showing 5 of 425 active programs.
Approved assets (149)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ezetimibe | 38 |
| Montelukast | 33 |
| Desloratadine | 24 |
| Mometasone Furoate Nasal Spray | 21 |
| ATORVASTATIN | 17 |
Showing 5 of 149 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 75% hit target (n=20) | 53% on time (n=17) |
Journals published in (200)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The American journal of cardiology | 31 |
| Journal of hypertension | 30 |
| Current medical research and opinion | 26 |
| Circulation | 25 |
| Hypertension (Dallas, Tex. : 1979) | 21 |
Showing 5 of 200 journals.
SEC-reported annual financials (8)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 6,216,000,000 | 187,000,000 | 366,000,000 |
| 2024 | 6,403,000,000 | 864,000,000 | 469,000,000 |
| 2023 | 6,263,000,000 | 1,023,000,000 | 528,000,000 |
| 2022 | 6,174,000,000 | 917,000,000 | 471,000,000 |
| 2021 | 6,304,000,000 | 1,351,000,000 | 339,000,000 |
| 2020 | 6,532,000,000 | 2,160,000,000 | 210,000,000 |
| 2019 | 7,777,000,000 | 3,218,000,000 | 220,000,000 |
| 2018 | not reported | not reported | not reported |
Financing and grant events (7)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-26 | Other financing | not disclosed | Sec extracted |
| 2024-09-17 | Other financing | not disclosed | Sec extracted |
| 2024-05-17 | Debt financing | 1,000,000,000 | Sec extracted |
| 2024-05-17 | Debt financing | not disclosed | Sec extracted |
| 2023-06-30 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 7 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 16 |
| Iqvia Holdings Inc. | Uses vendor | 7 |
| Bayer (Germany) | Co sponsors trial with | 2 |
| Merck Frosst Canada Ltd. | Co sponsors trial with | 1 |
| Merck Shering-Plough JV Study | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (516)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-04-26 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-03-12 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2024-10-30 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-09-17 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 516 events.
Biomarker capability evidence (639)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
| ABCC6 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 639 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, us granted patents, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.